• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Dianthus Therapeutics Inc.

    8/8/24 4:26:28 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNTH alert in real time by email
    S-8 1 dnth-form_s-8-mid-2024.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 8, 2024

    Registration No. 333- 

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

     

     

     

     

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

     

     

     

     

     

     

     

    Dianthus Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

     

    Delaware

     

    81-0724163

     

     

    (State or Other Jurisdiction of

    Incorporation or Organization

     

    (I.R.S. Employer

    Identification No.)

     

     

     

     

     

     

     

     

     

     

     

     

    7 Times Square, 43rd Floor

    New York, NY 10036

     

     

    (Address of Principal Executive Offices, Zip Code)

     

     

     

     

     

     

     

     

     

     

     

    Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan

     

     

    (Full title of the plan)

     

     

     

     

     

     

     

     

     

     

     

     

    Adam M. Veness, Esq.

    Senior Vice President, General Counsel and Secretary

    Dianthus Therapeutics, Inc.

    7 Times Square, 43rd Floor

    New York, NY 10036

    (929) 999-4055

     

     

     

     

     

     

     

    Copies to:

     

     

    Ryan A. Murr, Esq.

    Branden C. Berns, Esq.

    Chris W. Trester, Esq.

    Gibson, Dunn & Crutcher LLP

    One Embarcadero Center, Suite 2600

    San Francisco, CA 94111

    Telephone: (415) 393-8200

    Facsimile: (415) 393-8306

     

     

     

     

     

     

     

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) registers an additional 2,931,820 shares of common stock, $0.001 par value per share (“Common Stock”), of Dianthus Therapeutics, Inc. (the “Registrant”) available for issuance under the Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (the “Incentive Plan”), which was adopted by the Registrant’s board of directors on March 14, 2024 and approved by the Registrant's stockholders on May 23, 2024 to amend and restate the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan.

    The additional shares are of the same class as other securities relating to the Incentive Plan for which the Registrant’s registration statement filed Form S-8 filed with the Securities and Exchange Commission (the “SEC”) on March 21, 2024, October 4, 2023, March 8, 2022, March 3, 2021, March 3, 2020, March 19, 2019, and June 22, 2018 (Registration Nos. 333-278151, 333-274865, 333-263358, 333-253815, 333-236853, 333-230387, and 333-225838), and which, together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8 and the shares of Common Stock registered hereunder with respect to the Incentive Plan are in addition to the shares of Common Stock registered on such registration statements.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information

    The documents containing the information specified in Part I of this Registration Statement will be delivered to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the instructions to Part I of Form S-8, such documents are not being filed with the SEC either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit

    Number

     

    Description

    4.1

     

    Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 12, 2023)

    4.2

     

    Third Amended and Restated By-laws (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 21, 2024)

    5.1*

     

    Opinion of Gibson, Dunn & Crutcher LLP

    23.1*

     

    Consent of Deloitte & Touche LLP, independent registered public accounting firm

    23.2*

     

    Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1)

    24.1*

     

    Power of Attorney (included on the signature page to this Registration Statement)

    99.1

     

    Second Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 28, 2024)

    107.1*

     

    Filing Fee Table

     

    * Filed herewith.

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)
    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)
    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and
    (iii)
    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     


     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on August 8, 2024.

     

     

    DIANTHUS THERAPEUTICS, INC.

     

     

     

    By:

    /s/ Ryan Savitz

     

    Name:

    Ryan Savitz

     

    Title:

    Chief Financial Officer and Chief Business Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Marino Garcia, Ryan Savitz and Adam Veness and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

     

    Signature

     

    Title

    Date

     

     

     

     

    /s/ Marino Garcia

     

    Chief Executive Officer, President and Director

    August 8, 2024

    Marino Garcia

     

    (Principal Executive Officer)

     

     

     

     

     

    /s/ Ryan Savitz

     

    Chief Financial Officer and Chief Business Officer

    August 8, 2024

    Ryan Savitz

     

    (Principal Financial Officer)

     

     

     

     

     

    /s/ Edward Carr

     

    Chief Accounting Officer

    August 8, 2024

    Edward Carr

     

    (Principal Accounting Officer)

     

     

     

     

     

    /s/ Alison F. Lawton

     

    Director and Chair of the Board

    August 8, 2024

    Alison F. Lawton

     

     

     

     

     

     

     

    /s/ Tomas Kiselak

     

    Director

    August 8, 2024

    Tomas Kiselak

     

     

     

     

     

     

     

    /s/ Anne McGeorge

     

    Director

    August 8, 2024

    Anne McGeorge

     

     

     

     

     

     

     

    /s/ Leon O. Moulder, Jr.

     

    Director

    August 8, 2024

    Leon O. Moulder, Jr.

     

     

     

     

     

     

     

    /s/ Paula Soteropoulos

     

    Director

    August 8, 2024

    Paula Soteropoulos

     

     

     

     

     

     

     

    /s/ Jonathan Violin

     

    Director

    August 8, 2024

    Jonathan Violin

     

     

     

     


    Get the next $DNTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNTH

    DatePrice TargetRatingAnalyst
    10/14/2025$56.00Buy
    Truist
    7/2/2025Outperform
    William Blair
    12/20/2024Buy
    TD Cowen
    10/3/2024$48.00Outperform
    Oppenheimer
    7/26/2024$58.00Outperform
    Robert W. Baird
    6/27/2024Overweight
    Cantor Fitzgerald
    5/16/2024$40.00Buy
    H.C. Wainwright
    2/15/2024$44.00Buy
    Stifel
    More analyst ratings

    $DNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Carr Edward

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    2/4/26 5:42:10 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, General Counsel and Sec. Veness Adam M

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    2/4/26 5:41:33 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Head of R&D Randhawa Simrat

    4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

    2/4/26 5:40:55 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $DNTH
    SEC Filings

    View All

    Truist initiated coverage on Dianthus Therapeutics with a new price target

    Truist initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $56.00

    10/14/25 8:48:52 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Dianthus Therapeutics

    William Blair initiated coverage of Dianthus Therapeutics with a rating of Outperform

    7/2/25 8:17:26 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Dianthus Therapeutics

    TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy

    12/20/24 7:31:45 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Dianthus Therapeutics Inc.

    EFFECT - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    2/2/26 12:15:35 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Dianthus Therapeutics Inc.

    S-3 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    1/28/26 4:25:11 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

    1/12/26 9:01:32 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Thursday, February 12, 2026 at 10:00 am EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website.

    2/5/26 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference

    NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the 44th Annual J.P. Morgan Healthcare conference in San Francisco. Marino Garcia, CEO of Dianthus Therapeutics, will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 p.m. EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About

    1/5/26 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

    LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function  Top-line results in healthy volunteers anticipated in 2H'26 Dianthus to provide update on indication prioritization in 1H'26 LBL-047 (DNTH212) has the potential to be a first-line biologic in multiple autoimmune disorders with patient-friendly S.C. self-administration and Q4W or less frequent dosing NANJING, China and NEW YORK and WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") (9887.HK), a clinical-stage biotechnology compan

    12/23/25 6:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

    Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company's Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experi

    5/22/25 4:10:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

    Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co

    3/5/25 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

    Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.

    11/29/23 4:05:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Financials

    Live finance-specific insights

    View All

    Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

    DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function  Demonstrated superior inhibition of pDCs vs. litifilimab in vitro and superior Ig reductions vs. povetacicept in NHPs highlight the potential for improved clinical benefit in severe autoimmune diseases DNTH212 has the potential to be a first line biologic in multiple autoimmune disorders with patient-friendly S.C. self-administration and Q4W or less frequent dosing IND cleared by FDA in September 2025 and expected to clear in China in Q4'25. Phase 1 study of DNTH212 expected to initiate in

    10/16/25 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile

    Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13 Claseprubart demonstrated a rapid and sustained onset of action, with both doses achieving statistically significant improvements in MG-ADL and QMG scores at Week 1 Claseprubart 300mg Q2W dose was also statistically significant and clinically meaningful across other key efficacy endpoints, including Minimal Symptom Expression (MSE), Myasthenia Gravis Composite (MGC) Score and the Myasthenia Gravis Quality of Life Scale (MG-QoL-15r) Bot

    9/8/25 7:00:00 AM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

    NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT. Investor Webcast & Conference Call InformationTo access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive

    9/7/25 6:25:00 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dianthus Therapeutics Inc.

    SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    12/3/24 9:19:18 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Dianthus Therapeutics Inc.

    SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    11/22/24 4:41:50 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

    SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

    11/14/24 5:48:32 PM ET
    $DNTH
    Biotechnology: Pharmaceutical Preparations
    Health Care